Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17357043 | 0.84 | TSHR (0.49) | POLBELANENPSR1MEN1LMNA | |
| SCHEMBL10876771 | 0.83 | ELANE (0.46) | POLBELANENPSR1TDP1MEN1 | |
| SCHEMBL17359392 | 0.78 | TSHR (0.49) | POLBELANELMNAL3MBTL1 | |
| SCHEMBL14086368 | 0.76 | LMNA (0.43) | POLBELANENPSR1MEN1LMNA | |
| SCHEMBL13675399 | 0.75 | POLB (0.41) | POLBELANENPSR1MEN1KMT2A | |
| SCHEMBL2720079 | 0.75 | POLB (0.59) | POLBTDP1MEN1LMNAKMT2A | |
| SCHEMBL5530694 | 0.74 | L3MBTL1 (0.50) | POLBELANENPSR1TDP1MEN1 | |
| SCHEMBL25591711 | 0.73 | ELANE (0.51) | POLBELANENPSR1TDP1MEN1 | |
| SCHEMBL10458230 | 0.72 | ELANE (0.47) | POLBELANENPSR1TDP1MEN1 | |
| SCHEMBL28707744 | 0.71 | MTNR1A (0.46) | POLBTDP1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296703-B2 | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | UNIVERSITY OF UTAH | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368208-A1 | Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors | BTK, SYK, LYN | POLB 3854/4885ELANE 3439/4885NPSR1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.